Gencirq, Inc.
- UEI
- FHCTH7DWM2E3
- CAGE
- 875Q3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- gencirq.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Vedanta Biosciences, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vulcan Biologics Inc. | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Petri Bio Inc. | Torrance, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Topaz Biosciences, Inc. | Emeryville, CA | — |
About the company
Gencirq, Inc. is a biotechnology company that specializes in engineered bacteria therapies, leveraging advances in synthetic biology to engineer bacteria for the treatment of disease. Their technology allows bacteria to selectively colonize the body and deliver therapeutic payloads. Gencirq is a corporate entity registered as a for-profit small business in the federal System for Award Management (SAM).
Gencirq has been awarded several Small Business Innovation Research (SBIR) contracts from the National Institutes of Health (NIH) to develop bacterial therapeutics. In 2020, they received a $1.5 million SBIR Phase II award from NIH's National Center for Advancing Translational Sciences to further their bacterial synchronized lysis circuit platform for delivering therapeutics. This total small business set-aside contract involves engineering bacteria to release drugs at specific target sites. Gencirq also obtained a $299,300 SBIR Phase I contract from NIH's National Cancer Institute in 2019 to engineer probiotics for delivering chemopreventative agents to the gut. Another $225,000 SBIR Phase I award from NIH in 2019, designated for COVID-19 response, funded development of a screening platform using Gencirq's genetic lysis circuit technology. All of these firm-fixed-price contracts have supported Gencirq's core capabilities in synthetic biology and bacterial therapeutics as a small business contractor for federal health research agencies.
Quick answers
Is Gencirq, Inc. registered in SAM.gov?
Gencirq, Inc.'s SAM.gov registration expired on November 28, 2024.
What is Gencirq, Inc.'s most recent federal award?
Gencirq, Inc.'s most recent federal contract award is Sbir phase II, topic 016: development of a bacterial synchronized lysis circuit platform to deliver therapeutics (75N95020C00019), from National Institute on Drug Abuse (NIH), on September 26, 2020.
On GovTribe
See Gencirq, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors